Verified factor-similar pair

BMVP vs PTL

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

UMD
Similarity score
83
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • PTL has the higher backtested relative Sharpe (1.381 vs 0.859).
  • PTL has the lower published fee (0.09% vs 0.29%).
  • BMVP is cheaper on dividend valuation (64 vs 111, where 100 is each fund's historical median).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

BMVP

Invesco Bloomberg MVP Multi-factor ETF
UMD
Adj. R2
0.894
Rel. Sharpe
0.859
Mkt beta
0.96
AUM
US$101M
MER
0.29%
Valuation
64

PTL

Inspire 500 ETF
UMD
Adj. R2
0.891
Rel. Sharpe
1.381
Mkt beta
0.96
AUM
US$718M
MER
0.09%
Valuation
111

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
BMVP
+0.28
|t|
+7.1
PTL
+0.19
|t|
+1.6
diff +0.09
HML
BMVP
+0.07
|t|
+1.7
PTL
+0.10
|t|
+0.7
diff -0.03
RMW
BMVP
+0.18
|t|
+3.8
PTL
+0.07
|t|
+0.6
diff +0.11
CMA
BMVP
+0.03
|t|
+0.4
PTL
+0.13
|t|
+1.0
diff -0.10
UMD
BMVP
+0.13
|t|
+5.5
PTL
+0.19
|t|
+2.1
diff -0.06

Why This Pair Matches

Exposure level
82
Exposure shape
92
Mkt beta diff
0.00
Rel. Sharpe diff
0.523

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

BMVP fund page PTL fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.